Filippo Cauti

Dr. Filippo Cauti

Cardiac Arrhythmia Unit. Fatebenefratelli Hospital. Rome. Italy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2012 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
PDF file
DMDamiano Magrì
Damiano Magrì
PPPietro Palermo
Pietro Palermo
FCFilippo Cauti
Filippo Cauti
MCMauro Contini
Mauro Contini
SFStefania Farina
Stefania Farina
PAPiergiuseppe Agostoni
Piergiuseppe Agostoni
SUMMARY: Aim: To assess the effect of chronotropic incompetence on functional capacity in chronic heart failure (CHF) patients, as evaluated as NYHA and peak oxygen consumption (pVO2), focusing on the presence and dose of β‐blocker treatment. Methods: Nine hundred and sixty‐seven consecutive CHF patients were evaluated, 328 of whom were discarded because they failed to meet the study criteria. Of the 639 analyzed, 90 were not treated with β‐blockers whereas the other 549 were. The latter were further subdivided in high (n = 184) and low (n = 365) β‐blockers daily dose group in accordance with an arbitrary cut‐off of 25 mg for carvedilol and of 5 mg for bisoprolol. Failure to achieve 80% of the percentage of maximum age predicted peak heart rate (%Max PHR) or of HR reserve (%HRR) constituted chronotropic incompetence. Results: No differences were found in NYHA or pVO2 between patients with and without β‐blockers and, similarly, between high and low β‐blocker dose groups. Twenty and sixty‐nine percent of not β‐blocked patients showed chronotropic incompetence according to %Max PHR and %HRR, respectively, whereas this prevalence rose to 61% and 84% in those on β‐blocker therapy. Patients taking β‐blockers without chronotropic incompetence, as inferable from both %Max PHR and %HRR, showed higher NYHA and pVO2 regardless of drug dose, whereas, in not β‐blocked patients, only %HRR revealed a difference in functional capacity. At multivariable analysis, HR increase during exercise (ΔHR) was the variable most strongly associated to pVO2 (β: 0.572; SE: 0.008; P < 0.0001) and NYHA class (β: −0.499; SE: 0.001; P < 0.0001). Conclusions: ΔHR is a powerful predictor of CHF severity regardless of the presence of β‐blocker therapy and of β‐blocker daily dose.

23 March 2021 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
FCFilippo Cauti
Filippo Cauti
PRPietro Rossi
Pietro Rossi
PSPhilipp Sommer
Philipp Sommer
The implantable defibrillator has revolutionized the history of sudden cardiac death prevention in patients with structural heart disease. For decades, starting from open heart surgery approaches, there has been growing evidence from experimental and clinical studies on the electro-anatomical substrate favouring ventricular arrhythmias. Development of percutaneous techniques for mapping and ablation of ventricular tachycardias (VTs) have augmented progressively the clinical opportunity for VT treatment especially to manage arrhythmic storms. Despite the fast evolution in the development of new technologies, 1 we are witnessing arrhythmic recurrences also in patients undergoing multiple attempts of catheter ablation. This is particularly true for VTs in subjects with nonischaemic cardiomyopathy. 2, 3

19 February 2021 in Sensors
Verified
Journal Article
Open access
PDF file
Martina ZaltieriMartina Zaltieri
Martina Zaltieri
Carlo MassaroniCarlo Massaroni
Carlo Massaroni
FCFilippo Cauti
Filippo Cauti
Emiliano SchenaEmiliano Schena
Emiliano Schena
Cardiac radiofrequency ablation (RFA) has received substantial attention for the treatment of multiple arrhythmias. In this scenario, there is an ever-growing demand for monitoring the temperature trend inside the tissue as it may allow an accurate control of the treatment effects, with a consequent improvement of the clinical outcomes. There are many methods for monitoring temperature in tissues undergoing RFA, which can be divided into invasive and non-invasive. This paper aims to provide an overview of the currently available techniques for temperature detection in this clinical scenario. Firstly, we describe the heat generation during RFA, then we report the principle of work of the most popular thermometric techniques and their features. Finally, we introduce their main applications in the field of cardiac RFA to explore the applicability in clinical settings of each method.

18 July 2025 in European Heart Journal
Verified
Journal Article
Closed access
Giovanni PerettoGiovanni Peretto
Giovanni Peretto
MMMarco Merlo
Marco Merlo
AAAlessandro Ambrosi
Alessandro Ambrosi
EBElena Bacigalupi
Elena Bacigalupi
Andrea VillatoreAndrea Villatore
Andrea Villatore
GSGianfranco Sinagra
Gianfranco Sinagra
Background and Aims: The prediction of the first major arrhythmic event (MAE) is still an unmet need in the recently defined scenario of non-dilated left ventricular cardiomyopathy (NDLVC). Methods: A cohort of 337 patients with NDLVC and no history of MAE was retrospectively identified at two large centres. Patient-tailored diagnostic workup included cardiac magnetic resonance (CMR), endomyocardial biopsy, and genetic testing. The primary endpoint was the occurrence of the first MAE, including sustained ventricular tachycardia (VT), ventricular fibrillation, or appropriate implantable cardioverter-defibrillator therapy, by 60-month follow-up. A pool of 216 NDLVC patients from 11 European centres served as a validation cohort. Results: In the study cohort (mean age 37 ± 15 years, 62% male), the mean left ventricular ejection fraction (LVEF) was 52 ± 8%, and 79% of patients had late gadolinium enhancement (LGE) at baseline CMR. By 60-month follow-up, 51 patients (15%) experienced a MAE. The primary endpoint was predicted by male sex [hazard ratio (HR) 2.4, 95% confidence interval (CI) 1.3–4.4, P = .007], baseline non-sustained VT (HR 3.1, 95% CI 1.7–5.6, P < .001), LVEF < 45% (HR 5.5, 95% CI 2.7–11.0, P < .001), septal (HR 2.0, 95% CI 1.0–4.0, P = .046) and ring-like pattern of LGE (HR 1.3, 95% CI .6–2.6, P = .54), pathogenic/likely pathogenic variants in guideline-defined high-risk genes (HR 4.6, 95% CI 2.3–9.1, P < .001), and biopsy/CMR-proven myocardial inflammation (HR 15.7, 95% CI 6.1–40.3, P < .001). The results were confirmed in the validation cohort (Uno’s C-index 0.81, 95% CI .75–.88). A novel risk score was subsequently derived. Conclusions: In NDLVC, male sex, non-sustained VT, LVEF < 45%, septal and ring-like LGE, high-risk genotypes, and myocardial inflammation predicted the first episode of MAE by 60 months.

13 April 2021 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
FSFrancesco Solimene
Francesco Solimene
MSMario Giannotti Santoro
Mario Giannotti Santoro
ASAntonio De Simone
Antonio De Simone
MMMaurizio Malacrida Msc
Maurizio Malacrida Msc
GSGiuseppe Stabile
Giuseppe Stabile
LSLuca Segreti
Luca Segreti

1 August 2023 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
RPRossi Pietro
Rossi Pietro
FCFilippo Cauti
Filippo Cauti
MNMarta Niscola
Marta Niscola
MMMichele Magnocavallo
Michele Magnocavallo
MPMarco Polselli
Marco Polselli
SBStefano Bianchi
Stefano Bianchi
BACKGROUND: The analysis of the wave-front activation patterns is crucial for the comprehension and treatment of ventricular tachycardia (VT). The ventricular electrograms duration map (VEDUM) is a potential method to identify areas (VEDUM area) with slow and inhomogeneous activation. There is no available data on the characteristics and the arrhythmogenic role of VEDUM areas identified during sinus/paced rhythm. METHODS: Patients referred for VT ablation were enrolled at 3 different centers. VEDUM maps during sinus/paced rhythm as well as substrate and functional maps were created; activation mapping was performed for all hemodynamically tolerated VT. RESULTS: Thirty-two patients (mean age:70.1±9.4 years; males 93.8%) were enrolled. The VEDUM approach was achieved in all patients and the mean size of the VEDUM area was 12.1±6.9 cm 2 (interquartile range, 7.8–14.9 cm 2 ). A significative difference was observed between the electrogram duration in the VEDUM area and the normal tissue (163.7 ms [interquartile range, 142.3–199.2 ms]; versus 65.5 ms [interquartile range, 59.5–76.2 ms]; P <0.001). The VEDUM area was visualized in a dense scar (<0.5 mV) in 19 (59.4%) patients. A deceleration zone and late potentials were recorded inside the VEDUM area in 56.3% and 81.3%, respectively. When a complete VT activation mapping was available, the isthmus projected in the VEDUM area in 93.5% of patients; 8 of them had multiple VTs mapped and in the 87.5% all VT isthmuses were included in the VEDUM area. CONCLUSIONS: VEDUM maps allow the identification of discrete areas of inhomogeneous and slow conduction. They represent a potential target for VT ablation, including patients with multiple morphologies.